Sprifermin

Sprifermin is a recombinant form of human fibroblast growth factor 18 (FGF18) that is under investigation for the treatment of osteoarthritis (OA). It is being developed by the Danish pharmaceutical company Merck KGaA and is currently in phase III clinical trials.

Mechanism of action

Sprifermin works by stimulating the growth of cartilage cells, known as chondrocytes. This is achieved through the activation of the fibroblast growth factor receptor 3 (FGFR3) pathway, which is involved in the regulation of cartilage metabolism and joint homeostasis.

Clinical trials

Sprifermin has been tested in several clinical trials for the treatment of osteoarthritis. In a phase II trial, it was found to increase cartilage thickness and volume in the knee joint of patients with OA. The ongoing phase III trial aims to confirm these results and assess the long-term safety and efficacy of the drug.

Potential benefits

If successful, sprifermin could offer a new treatment option for patients with OA, a condition for which there is currently no cure. By promoting the growth of new cartilage, it could potentially slow or even reverse the progression of the disease.

See also

• Osteoarthritis
• Fibroblast growth factor 18
• Fibroblast growth factor receptor 3
• Chondrocytes
• Merck KGaA